MiNK Therapeutics (NASDAQ:INKT) Announces Earnings Results

MiNK Therapeutics (NASDAQ:INKT) announced its quarterly earnings data on Tuesday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.12), Zacks reports.

MiNK Therapeutics Stock Performance

Shares of INKT stock opened at $8.24 on Wednesday. The firm’s 50 day moving average price is $8.91 and its two-hundred day moving average price is $7.75. The stock has a market cap of $32.66 million, a PE ratio of -2.11 and a beta of 0.16. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $19.00.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of MiNK Therapeutics in a research note on Tuesday.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.